How does combined HRT work for perimenopause?

Combined hormone replacement therapy (HRT) contains two hormonal components: an estrogen and a progestogen. Understanding why both are included, and how each works, helps clarify what combined HRT does and why the specific formulation and delivery route matter clinically.

The estrogen component addresses the wide range of symptoms that arise from estrogen decline during perimenopause. Estrogen works by binding to estrogen receptors throughout the body, which are present in almost every tissue: the brain, hypothalamus, cardiovascular system, bones, skin, vagina, bladder, and muscle. In the hypothalamus, estrogen stabilizes the thermoregulatory zone, reducing the frequency and severity of hot flashes and night sweats by preventing the erratic vasomotor responses that estrogen loss triggers. In the brain's limbic system, estrogen supports neurotransmitter systems including serotonin, dopamine, and acetylcholine, improving mood stability, reducing anxiety and irritability, and supporting cognitive function. In vaginal and urethral tissue, estrogen restores thickness, elasticity, and moisture, addressing dryness, discomfort during sex, and urinary urgency. In bone, estrogen reduces osteoclast activity, slowing the accelerated bone loss that begins during perimenopause.

The progestogen component serves a specific and critical purpose: protecting the uterine lining from the over-stimulation that estrogen alone would cause. When estrogen acts on the uterus without progestogen opposition, it promotes continuous growth of the endometrial lining (endometrial hyperplasia), which over time significantly elevates the risk of endometrial cancer. Adding a progestogen counteracts this by promoting endometrial differentiation and periodic shedding or by maintaining a thin, stable lining. Women who have had a hysterectomy do not need a progestogen because they no longer have a uterus to protect.

Progestogens come in different forms that affect tolerability and risk. Synthetic progestins such as medroxyprogesterone acetate (MPA) and norethisterone have been used for decades. Oral micronized progesterone (bioidentical progesterone, sold as Prometrium or in generic form) is increasingly preferred by many providers based on its better tolerability profile for mood, lower apparent breast cancer risk compared to synthetic progestins in observational data, and favorable effects on sleep. The Mirena levonorgestrel IUD is another progestogen delivery option, releasing progestin locally into the uterus with minimal systemic effect.

There are two main regimens for combined HRT. Sequential (cyclical) combined HRT administers estrogen continuously every day and adds progestogen for 10 to 14 days per month. This mimics the luteal phase of a natural cycle and produces a monthly withdrawal bleed when progestogen is stopped. This regimen is often preferred for women who are still menstruating or who are in early perimenopause, as it maintains a cycle-like pattern. Continuous combined HRT administers both estrogen and progestogen every day without a break. This aims to produce no bleeding at all once the uterus adjusts to the combined hormonal input, usually within the first few months. It is generally preferred for women who are definitively postmenopausal.

The route of estrogen delivery is clinically important beyond mere convenience. Transdermal estrogen (patches, gels, sprays) bypasses hepatic first-pass metabolism, meaning it does not pass through the liver before entering systemic circulation. This avoids the liver's production of clotting factors and inflammatory proteins that oral estrogen stimulates, resulting in significantly lower risk of venous thromboembolism (blood clots) and stroke compared to oral estrogen. Multiple epidemiological studies, including large cohort analyses from the UK and France, support this risk difference. For women with cardiovascular risk factors, migraines, or personal risk of clotting, transdermal routes are strongly preferable.

Tracking your symptoms over time, using a tool like PeriPlan, can help you monitor symptom improvement after starting combined HRT and identify any residual symptoms, side effects such as breast tenderness or breakthrough bleeding, or areas where your regimen needs adjustment.

When to talk to your doctor: Discuss combined HRT with a provider who reviews your personal and family history of breast cancer, blood clots, stroke, liver disease, and cardiovascular risk. Mention your preferences about bleeding, since the choice between sequential and continuous regimens depends partly on where you are in the transition and how you feel about having a monthly bleed. Ask specifically about transdermal estrogen options and micronized progesterone if you have any cardiovascular risk factors or prior progestogen intolerance.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.